510(k) K262893
K262893 is an FDA 510(k) premarket notification submitted by Revvity, Inc. for the device "Eonis SMA kit". The FDA issued a decision of Substantially Equivalent on Sep 30, 2026. The device falls under product code QUE (Spinal Muscular Atrophy Newborn Screening Test System), a Class II device regulated under 21 CFR 866.5980.
Clearance details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- Sep 30, 2026
- Date Received
- Aug 17, 2026
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device classification
- Device Name
- Spinal Muscular Atrophy Newborn Screening Test System
- Device Class
- Class II
- Regulation Number
- 866.5980
- Review Panel
- MG
- Submission Type
- 510(k)
A Spinal Muscular Atrophy (SMA) newborn screening test system is a prescription device intended to detect homozygous deletion of exon 7 or other similar mutations in the SMN1 (Survival Motor Neuron 1) gene of DNA obtained from dried blood spot specimens on filter paper using a polymerase chain reaction-based test as an aid in screening newborns for SMA. Presumptive positive results are intended to be followed up by diagnostic confirmatory testing.
Need the full FDA record for Revvity, Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.